Titlebook: Resistance to Molecular Therapies for Hepatocellular Carcinoma; Augusto Villanueva Book 2017 Springer International Publishing AG 2017 Can

脆弱么

978-3-319-85850-0Springer International Publishing AG 2017

GRUEL

花爭吵

Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carciews the results of clinical trials of systemic therapy for patients with sorafenib-resistant HCC and preclinical studies exploring mechanisms and biomarkers of sorafenib resistance in HCC. The insights and limitations of these studies are discussed.

反復(fù)拉緊

Adj異類的

Graduated

Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma,mong tumors of different patients, multiple nodules of one patient and even within a single tumor nodule. As demonstrated in other tumor types, this diversity may contribute to the development of drug resistance. The mechanisms behind intra-tumoral heterogeneity are not yet fully understood, and pot

ORE

整體

Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance,rldwide, in part due to limited effective treatment and the rapid development of resistance. While many studies have focused on the cellular changes that drive resistance to therapy, little attention has been given to the role that liver tumor microenvironment plays in this process. Liver fibrosis,

epinephrine

Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance,e phenotypic and molecular heterogeneities observed in hepatocellular carcinoma (HCC) which hampers therapeutic progress. The hypothesis infers that CSCs share functional properties similar to adult stem cells, such as self-renewal and differentiation capacity, and are exclusively responsible for tu

micronutrients

Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carci tumor microenvironment, thus rendering the exploration of strategies to reverse sorafenib resistance an extremely challenging task. This chapter reviews the results of clinical trials of systemic therapy for patients with sorafenib-resistant HCC and preclinical studies exploring mechanisms and biom